|Bid||4.1300 x 1300|
|Ask||4.3900 x 1100|
|Day's range||4.0200 - 4.4000|
|52-week range||1.6300 - 5.5000|
|Beta (5Y monthly)||2.06|
|PE ratio (TTM)||N/A|
|Earnings date||04 Mar 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.25|
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...
Harlan Waksal became the CEO of Kadmon Holdings, Inc. (NYSE:KDMN) in 2014. This report will, first, examine the CEO...
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kadmon Holdings, Inc. (NYSE:KDMN) shareholders will doubtless be very grateful to see the share price up 50% in the...
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Every investor in Kadmon Holdings, Inc. (NYSE:KDMN) should be aware of the most powerful shareholder groups. Large...